Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Tremblay

Showing results (31-40 of 109) with videos related to

Pageof 11
Sort By:
Annals of Hematology|August 2, 2025
The evaluation, management, and future of indolent systemic mastocytosisArjun Syal, Jennifer Toh, Alissa McInerney, et al.
Quality Management in Health Care|May 28, 2021
A Rapid Guidance Process for the Development of an Anticoagulation Protocol in the COVID-19 PandemicDouglas Tremblay, Andrew S Dunn, William K Oh
Clinical Lymphoma, Myeloma & Leukemia|September 19, 2015
Systemic Mastocytosis: Clinical Update and Future DirectionsDouglas Tremblay, Nicole Carreau, Marina Kremyanskaya, et al.
European Journal of Haematology|May 1, 2020
Soluble interleukin-2 receptor (sIL-2r) level is a limited test for the diagnosis of adult secondary hemophagocytic lymphohistiocytosisLeonard Naymagon, Douglas Tremblay, Kevin Troy, et al.
Surgery|December 28, 2020
Characteristics, anticoagulation, and outcomes of portal vein thrombosis after intra-abdominal surgeryLeonard Naymagon, Douglas Tremblay, John Mascarenhas, et al.
Molecular Cytogenetics|October 22, 2025
Long-read sequencing unmasks a cryptic three-way translocation resulting in an ETV6::PDGFRB fusionJoseph Tripodi, Douglas Tremblay, Daiva Ahire, et al.
Journal of Thrombosis and Thrombolysis|September 8, 2019
The role of anticoagulation in pylephlebitis: a retrospective examination of characteristics and outcomesLeonard Naymagon, Douglas Tremblay, Thomas Schiano, et al.
Quality Management in Health Care|July 2, 2016
A Simple and Powerful Risk-Adjustment Tool for 30-day Mortality Among InpatientsDouglas Tremblay, Julia H Arnsten, William N Southern
Frontiers in Endocrinology|July 17, 2023
Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitorDouglas Tremblay, Mikaela Dougherty, John Mascarenhas, et al.
Frontiers in Oncology|March 5, 2021
Evaluation of Therapeutic Strategies to Reduce the Number of Thrombotic Events in Patients With Polycythemia Vera and Essential ThrombocythemiaDouglas Tremblay, Heidi E Kosiorek, Amylou C Dueck, et al.
Pageof 11

Showing results (31-40 of 109) with videos related to

Sort By:
Pageof 11
Annals of Hematology|August 2, 2025
The evaluation, management, and future of indolent systemic mastocytosisArjun Syal, Jennifer Toh, Alissa McInerney, et al.
Quality Management in Health Care|May 28, 2021
A Rapid Guidance Process for the Development of an Anticoagulation Protocol in the COVID-19 PandemicDouglas Tremblay, Andrew S Dunn, William K Oh
Clinical Lymphoma, Myeloma & Leukemia|September 19, 2015
Systemic Mastocytosis: Clinical Update and Future DirectionsDouglas Tremblay, Nicole Carreau, Marina Kremyanskaya, et al.
European Journal of Haematology|May 1, 2020
Soluble interleukin-2 receptor (sIL-2r) level is a limited test for the diagnosis of adult secondary hemophagocytic lymphohistiocytosisLeonard Naymagon, Douglas Tremblay, Kevin Troy, et al.
Surgery|December 28, 2020
Characteristics, anticoagulation, and outcomes of portal vein thrombosis after intra-abdominal surgeryLeonard Naymagon, Douglas Tremblay, John Mascarenhas, et al.
Molecular Cytogenetics|October 22, 2025
Long-read sequencing unmasks a cryptic three-way translocation resulting in an ETV6::PDGFRB fusionJoseph Tripodi, Douglas Tremblay, Daiva Ahire, et al.
Journal of Thrombosis and Thrombolysis|September 8, 2019
The role of anticoagulation in pylephlebitis: a retrospective examination of characteristics and outcomesLeonard Naymagon, Douglas Tremblay, Thomas Schiano, et al.
Quality Management in Health Care|July 2, 2016
A Simple and Powerful Risk-Adjustment Tool for 30-day Mortality Among InpatientsDouglas Tremblay, Julia H Arnsten, William N Southern
Frontiers in Endocrinology|July 17, 2023
Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitorDouglas Tremblay, Mikaela Dougherty, John Mascarenhas, et al.
Frontiers in Oncology|March 5, 2021
Evaluation of Therapeutic Strategies to Reduce the Number of Thrombotic Events in Patients With Polycythemia Vera and Essential ThrombocythemiaDouglas Tremblay, Heidi E Kosiorek, Amylou C Dueck, et al.
Pageof 11